| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| Other Sizes |
| Targets |
Bisabolol oxide A targets inflammatory pathways, contributing to anti-inflammatory, gastrointestinal, and antipruritic actions. As a sesquiterpene oxide from chamomile, it modulates inflammatory responses. The compound's mechanism involves the modulation of inflammatory mediators and signaling pathways. Its anti-inflammatory activity makes it valuable for research in inflammation and skin conditions. Further research is needed to identify its specific molecular targets and mechanisms of action.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that Bisabolol oxide A exhibits anti-inflammatory, gastrointestinal, and antipruritic actions. As one of the main constituents of German chamomile, its bioactivities have been characterized. The compound's anti-inflammatory effects have been evaluated in various in vitro systems. These in vitro findings support its potential applications in inflammation research and natural product pharmacology.
|
| ln Vivo |
In vivo studies of Bisabolol oxide A are limited as the compound is primarily used as a research chemical. As a component of German chamomile, it contributes to the plant's traditional uses for inflammation and gastrointestinal conditions. Its anti-inflammatory and antipruritic actions suggest potential for in vivo evaluation in models of inflammation and skin conditions. However, comprehensive in vivo pharmacological studies specifically targeting Bisabolol oxide A are not well documented.
|
| Enzyme Assay |
In vitro enzyme inhibition assays for Bisabolol oxide A typically involve testing its anti-inflammatory activity. Anti-inflammatory activity is assessed by measuring inhibition of inflammatory enzyme activity or cytokine production. The compound's purity (≥95.0%) and identity are confirmed using analytical chemistry methods such as nuclear magnetic resonance spectroscopy, high-performance liquid chromatography, and mass spectrometry. All assays are performed with appropriate controls and standardized protocols.
|
| Cell Assay |
In vitro cell-based assays for Bisabolol oxide A involve culturing immune cells to evaluate its anti-inflammatory effects. Cells are treated with varying concentrations of the compound and stimulated with inflammatory stimuli. Pro-inflammatory cytokine production is measured by ELISA. Cell viability is assessed using MTT or similar colorimetric assays to ensure that observed effects are not due to cytotoxicity. All experiments are performed in triplicate with appropriate controls to ensure statistical reliability.
|
| Animal Protocol |
In vivo animal experiments for Bisabolol oxide A would be conducted to evaluate its anti-inflammatory and antipruritic activities. Animals with induced inflammation or pruritus would be treated with the compound and symptoms assessed. Parameters assessed would include inflammatory markers, skin condition, and histopathology. Control groups receiving vehicle alone would be included for comparison. All procedures would comply with institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Bisabolol oxide A reflect its nature as a sesquiterpene oxide. It has a molecular weight of 238.37 and the molecular formula C15H26O2. The compound is slightly soluble in water (1 g/L at 25°C). As a lipophilic sesquiterpene, it would be absorbed through the gastrointestinal tract and distributed throughout the body. Complete pharmacokinetic profiling would require further systematic studies.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Bisabolol oxide A has been evaluated in the context of its use as a research chemical. As a naturally occurring component of chamomile, it is expected to have a favorable safety profile at research concentrations. The compound has a purity of ≥95.0%. Proper handling procedures including use of personal protective equipment are recommended when working with pure compound. The compound is not approved for human therapeutic use and is intended for research purposes only.
|
| References | |
| Additional Infomation |
Bisabolol oxide A belongs to the oxacyclohexane class of compounds. It has been reported that bisabolol oxide A is found in chamomile (Matricaria chamomilla), and relevant data is available. See also: Chamomile (partial).
Bisabolol oxide A (CAS# 22567-36-8) is also known as (-)-α-bisabolol oxide A. It has the molecular formula C15H26O2 and a molecular weight of 238.37. The compound is a naturally occurring sesquiterpene oxide derived from α-bisabolol and found in chamomile. It is one of the main constituents of German chamomile with anti-inflammatory, gastrointestinal, and antipruritic actions. The compound has a purity of ≥95.0%. |
| Molecular Formula |
C15H26O2
|
|---|---|
| Molecular Weight |
238.37
|
| Exact Mass |
238.193
|
| CAS # |
22567-36-8
|
| PubChem CID |
13092559
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
0.982 g/cm3
|
| Boiling Point |
327.7ºC at 760 mmHg
|
| Flash Point |
125.9ºC
|
| Vapour Pressure |
1.5E-05mmHg at 25°C
|
| Index of Refraction |
1.49
|
| LogP |
3.441
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
17
|
| Complexity |
319
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CC1CC[C@H]([C@@]2(CC[C@H](O)C(C)(C)O2)C)CC=1
|
| InChi Key |
WJHRAVIQWFQMKF-IPYPFGDCSA-N
|
| InChi Code |
InChI=1S/C15H26O2/c1-11-5-7-12(8-6-11)15(4)10-9-13(16)14(2,3)17-15/h5,12-13,16H,6-10H2,1-4H3/t12-,13+,15+/m1/s1
|
| Chemical Name |
(3S,6S)-2,2,6-trimethyl-6-[(1S)-4-methylcyclohex-3-en-1-yl]oxan-3-ol
|
| Synonyms |
Bisabolol oxide A
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1952 mL | 20.9758 mL | 41.9516 mL | |
| 5 mM | 0.8390 mL | 4.1952 mL | 8.3903 mL | |
| 10 mM | 0.4195 mL | 2.0976 mL | 4.1952 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
